Compare ADMA Biologics Inc (ADMA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Wells Fargo & Co — how do they compare? ADMA Biologics Inc trades at $9.2 (market cap $2.13B), while Wells Fargo & Co trades at $85.48 (market cap $266.79B). The key difference: Wells Fargo & Co is far larger — about 125.3× ADMA Biologics Inc's market cap, and Wells Fargo & Co pays a 2.06% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WFC | |
|---|---|---|
Market Cap | $2.13B | $266.79B |
Sector | Health | Financials |
52-Week High | $20.38 | $96.40 |
52-Week Low | $7.60 | $73.42 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Wells Fargo (WFC) trades at $87.21, up 1.99% on the day, with a bullish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.52, net income margin of 25.53%, and ROE of 12.7%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company announced a dividend of $0.45 payable in June 2026, and Q2 2026 earnings are expected on July 14, 2026, with an EPS estimate of 1.73.
The outlook for WFC is cautiously optimistic, supported by analyst consensus with a $98.25 price target and 45% buy ratings. Key opportunities include potential earnings growth and dividend increases post-Fed stress tests. Risks involve volatile cash flows, regulatory changes impacting debit card fees, and competitive pressures in the banking sector. The stock's valuation remains attractive, but investors should monitor upcoming earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
